Prestige Consumer Healthcare Inc. (NYSE:PBH) Position Reduced by Ameriprise Financial Inc.

Ameriprise Financial Inc. cut its position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 52.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 116,007 shares of the company’s stock after selling 129,220 shares during the quarter. Ameriprise Financial Inc. owned 0.23% of Prestige Consumer Healthcare worth $9,059,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Kestra Investment Management LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at about $27,000. CIBC Private Wealth Group LLC lifted its stake in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company’s stock valued at $34,000 after buying an additional 152 shares in the last quarter. Headlands Technologies LLC purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at about $40,000. Johnson Financial Group Inc. purchased a new stake in Prestige Consumer Healthcare during the fourth quarter valued at about $93,000. Finally, Huntington National Bank lifted its stake in Prestige Consumer Healthcare by 133.2% during the fourth quarter. Huntington National Bank now owns 1,481 shares of the company’s stock valued at $116,000 after buying an additional 846 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now owns 17,157 shares in the company, valued at $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Prestige Consumer Healthcare Trading Down 1.6%

NYSE:PBH opened at $87.55 on Wednesday. The stock’s 50 day moving average price is $83.46 and its 200 day moving average price is $82.08. Prestige Consumer Healthcare Inc. has a 52 week low of $62.35 and a 52 week high of $90.04. The company has a market capitalization of $4.33 billion, a P/E ratio of 20.50, a P/E/G ratio of 2.69 and a beta of 0.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, May 8th. The company reported $1.32 EPS for the quarter, topping analysts’ consensus estimates of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The firm had revenue of $296.52 million for the quarter, compared to the consensus estimate of $289.36 million. During the same quarter in the prior year, the company posted $1.02 earnings per share. The firm’s revenue was up 7.0% on a year-over-year basis. On average, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Canaccord Genuity Group upped their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a report on Friday, February 7th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a “hold” rating in a report on Thursday, May 8th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday. Oppenheimer upped their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an “outperform” rating in a report on Thursday, February 13th. Finally, DA Davidson upped their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare has an average rating of “Moderate Buy” and a consensus target price of $93.33.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.